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Introduction
In the midst of poor economy, corruption and political instability, infectious diseases have become one of the greatest disease burdens in Africa. Of all the population threatening disease burdens, Tuberculosis (TB) has emerged as the single leading cause of death from any single infectious agent and has continued to be a major public health problem all over the world. TB is caused by Mycobacterium tuberculosis and occasionally by Mycobacterium bovis and Mycobacterium africanium [1] . M. tuberculosis is a gram positive acid fast, slender-straight rod. The organism is a strict aerobe and thrives best in organs with relatively high oxygen tension. As such, apices of lungs, renal parenchyma and growing end of bones are common metastatic foci sites. In most cases, it is the causative organisms for the disease. On the other hand, M. bovis is a pathogen in the complex of bacteria that includes M. tuberculosis and its clinical characteristics is indistinguishable from M. tuberculosis TB in most cases [2] .
The bacteria that cause TB (M. tuberculosis and M-bovis, M-africanai) are responsible for lesions called tubercle in patients with TB, hence the organisms are known as tubercle bacilli. They are also known as acid-fast bacilli (AFB) [3] . The causative organism is transmitted exclusively by inhalation of infective droplets from patients with open pulmonary tuberculosis through coughing, sneezing, talking or spitting [4] . Concentration of droplet nuclei in contaminated air, length of time a person breaths in air and level of immunity (susceptibility to infection) are some of the factors which determine an individual's risk of exposure. Once infected with TB causing bacteria, a person can stay even for a life time and not develop the disease but in this healthy, asymptomatic but infected individual, the development of disease can be triggered most importantly by weakening of immune system especially by HIV infection [1] [2] . Overcrowding, substandard living, poor nutrition and interaction with other diseases increase risks to the TB disease and also results in high rates of reinfection as well as high morbidity and mortality in patients. People infected with tuberculosis very often originate from the most vulnerable sectors of society. These include those living in poverty, prisons and in poor working conditions. A reduction in stress, exposure to environmental pollution, overcrowding, poverty with better nutrition and interaction with health care workers reduces the risk of infection and the progression of the disease. After 5 years without treatment, 50% of primary TB patients often die, 25% will remain ill with chronic infectious TB and the remaining 25% will be spontaneously remitted by strong immune defenses without treatment [1] .
The status of the TB epidemic and progress in control of the disease since 1990 have been reported by World Health Organisation (WHO) annually since 1997. The assessment often included estimates of incidence, prevalence and mortality. More recently, it has also included assessment of progress towards the newer impact targets related to incidence, prevalence and mortality that have been set within the framework of the Millennium Development Goals (MDGs) and by the Stop TB Partnership. The global targets and indicators for TB control have been developed within the framework of the MDGs, Stop TB Partnership and WHO's World Health Assembly (Table 1) [5] . These were developed to halt and reverse TB incidence by 2015 and to halve prevalence and death rates by 2015 compared with a baseline of 1990. The outcome targets were to achieve a case detection rate of at least 70% under Directly Observed Treatment Short Course (DOTS) and to reach a treatment success rate of at least 85% in DOTS cohorts.
Overview of Global TB Burden
The prevalence, patterns of presentation and mortality from TB have been known to vary from one country to another and from one region of a country to the other. This variation depends on prevailing social factors The global burden of TB (per capita prevalence and death rates) will be reduced by 50% relative to 1990 levels By 2050
The global incidence of active TB will be less than 1 case per million population per year MDG, Millennium Development Goal such as socio-economic status of the people, malnutrition, crowded living conditions, incidence of HIV/AIDS, level of development of health infrastructures, quality of available control programmes and degree of drug resistance to antituberculous agents among other factors [6] [7] . Based on surveillance and survey data, there were an estimated 14.4 million cases of TB out of which 9.2 million new cases of TB occurred globally in 2006 (139 per 100,000). These numbers include 4.1 million (62 per 100,000) new smear-positive cases (Tables 2 and 3 ) and around 709,000 (7.7%) HIV-positive TB cases. In terms of incidence cases, India, China, Indonesia, South Africa and Nigeria rank first to fifth, respectively. In all these global cases, Africa accounts for 31% while Asia (South-East Asia and Western Pacific regions) accounts for 55%. As in 2007, the African Region accounted for most HIVpositive cases, being 85% in 2006. Most of the remaining cases were in the South-East Asia Region, mainly in India. Some African countries account for a strikingly large number of cases relative to their population. South Africa, for example, has 0.7% of the world's population but 28% of the global number of HIV-positive TB cases and 33% of HIV-positive cases in the African Region [5] .
With the number of new incident TB cases in 2006, there were an estimated 14.4 million prevalent cases (219/100 000) on average ( Table 2 ). An estimated 1.7 million people (25/100 000) died from TB in 2006, including those co-infected with HIV (231,000). The sequence of annual estimates up to 2006 suggests that all three major indicators of impact -incidence, prevalence and mortality per 100 000 population -are falling globally. In WHO assessment, prevalence was already in decline by 1990, mortality peaked before the year 2000 and incidence began to fall in 2003 ( Figure 1 ). TB prevalence continued to fall globally between 1990 and 2006 because, in Africa, the HIV epidemic caused a smaller increase in prevalence than in incidence or mortality. 
TB Treatment Strategies
Despite the often reported high morbidity resulting from TB infection, milestones in developing effective anti-tuberculosis drugs, TB continued to be a major public health problem all over the world [1] . The reasons for this deterioration in increased TB prevalence include improper diagnosis and treatment, poor adherence to medication, increased travel and migration, presence of multi-resistant TB and lately to the pandemic of HIV/AIDS [10] . As an attempt to reduce TB prevalence, WHO advocated the use of Directly Observed Treatment Short Course (DOTS) strategy [11] . The strategy for TB control was launched by the World Health Organisation in 1995. It was designed to ensure that a trained health worker or supervisor provides the prescribed TB drugs and watches the patient swallow every dose [1] . The five key components of DOTS are:
1. Political commitment with increased and sustained financing, 2. Case detection through qualityassured bacteriology, 3. Standardized treatment with supervision and patient support, 4. An effective drug supply and management system, and 5. Monitoring and evaluation system and impact measurement DOTS includes delivering the prescribed medication, checking for side effects, watching the patient swallow the medication, documenting the visit, counseling and answering patient questions. The strategy, although based around short course treatment regimens for a minimum of six months, also includes tenets such as political commitment, good management practices, sputum smear microscopy for diagnosis, and the direct observation of doses to ensure adherence. In addition, it includes registration of each patient detected, followed by standardized multi-drug treatment, with a secure supply of high quality anti-TB drugs for all patients in treatment, individual patient outcome evaluation to ensure cure and cohort evaluation to monitor overall programme performance. A degree of patient cooperation is required because they may conceal tablets in the mouth or try to avoid taking medications therefore careful vigilance is required by the person administering therapy through out the whole treatment period. Implementing DOTS appropriately requires investments in strengthened health systems including trained personnel, an effective procurement and drug distribution system, and an effective monitoring and surveillance system. In Nigeria, the DOTS strategy was adopted nationally following the Abuja Declaration in 2001, and is now being implemented in all states of the federation, and in virtually all the local government areas. As at the end of 2007, there were currently over 3000 DOTS centres in Nigeria [12] .
In 2006, WHO developed a new six point Stop TB Strategy which builds on the successes of DOTS while also explicitly addressing the key challenges facing TB. Its goal is to dramatically reduce the global burden of tuberculosis by 2015 by ensuring all TB patients, including for example, those co-infected with HIV and those with drugresistant TB, benefit from universal access to high-quality diagnosis and patient-centered treatment. The strategy also supports the development of new and effective tools to prevent, detect and treat TB. 
Outcomes of treatment in DOTS programmes
Before the implementation of DOTS, TB treatment in many resource poor settings was chaotic, non-standardised, and poorly monitored and consequently had little epidemiological impact on the incidence of TB [13] . Worldwide, the introduction of the DOTS strategy has led to improvements in treatment outcomes for many patients [5] . For many years, WHO has reported the success rate of DOTS in cohorts of patients in terms of 'Died', 'Failed', 'Defaulted', 'Transferred', and 'Not evaluated' ( [14] [15] , recurrent disease is still considered to be an important measure of the efficacy of tuberculosis treatment and also has a major impact on patients.
DOTS and Stop TB Programmes in Nigeria
Nigeria is now considered the world's fifth largest TB burden with nearly 450,000 estimated new cases annually [8] [9] . The public Health burden posed by TB is becoming increasingly important as the country's HIV/AIDS epidemic unfolds. There has been rapid progress in DOTS expansion in 2003, with relatively high treatment success. Unfortunately, political commitment has not yet been translated into strong support for the health system, and much of the approved government funding for health care has not been released for use in health programmes. This situation has discouraged a number of external donors, who are reluctant to provide additional funds while government funding is very limited. Although Nigeria has an extensive national Health infrastructure, it lacks the resources needed to function effectively.
With over 3000 DOTS centres and all the States of the federation and local governments being covered, 75% of the Nigeria's population is currently under the DOTS programme [12] . Although the case notification rate of TB in Nigeria has increased over the years, recent figures put the DOTS detection rate of new sputum smear positive to be very low (20%) while the treatment success of new sputum smear positive still falls below the WHO target of 85% [5] .
WHO has always included the data TB epidemiological data in their annual reports. According to the reports, treatment outcomes in Nigeria are typical of countries in Africa with many patients dying while on treatment or are reported as having defaulted. Most of these reports are based on estimates as accurate data are hardly available due to poor documentation and reporting systems that have existed in the health sector in Nigeria for decades. For example, there are indications that patients who have actually died are being reported as defaulted [5] . Although there are studies in some parts of the country, many of them are only reported in local journals that are not widely accessible and often involve small cohorts of TB patients. Some of the available studies are summarized in Table 5 . While the cure rate of some western states is similar to the national average, very low rates have been reported in Ile-Ife and some relatively rural parts of Edo State. The extremely high death rate (36.4%) and failure rate (17.1%) reported in Ile-Ife between 1991 and 2000 is not consummate with other available data.
The failure to detect a huge number of active TB cases which are primarily responsible for the spread of the infection has been identified in an earlier study [17] . Default from treatment has been reported to be highest during the continuation phase of treatment generally while HIV-positive patients had twice the risk of default during the intensive phase of the treatment than HIV-negative individuals. Also men were more likely to default than women [18] .
Dealing with Treatment Problems in Nigeria
The treatment of TB has constituted a major problem in Nigeria for several reasons. First, a lot of people with TB are still not detected and they are not able to access the treatment. Second, the number of new cases of TB is increasing in the country because of the epidemic of HIV/AIDS. Third, getting the TB programme to provide drugs and other TB services to all the communities has been [12, 19] . Sixth, poor adherence to medication and treatment is a major issue like in all other parts of the world [12, 20] . Long distance to the hospitals which limits the chances of patients' financing their treatment, lack of facility for home visit in most cases and poor supervision in under-aged children are some of the contributing factors for high treatment default rate which often results in the development of multidrugresistant TB [21] . HIV/TB co-infected patients are more likely to default from treatment as they experience progressive deterioration in their health status when compared to other patients [18] . Okeke and Aguwa [22] has found out that the private practitioners in Nigeria do not often effectively implement the DOTS programme, particularly in areas such as political commitment, case detection through sputum smear microscopy, standardized treatment for 6-8 months, uninterrupted drug supply and standardized recording and reporting system. Delay in seeking treatment has been reported to occur in as much as 83% of patients in Lagos [23] . This is dangerous since it has been estimated that every case of TB can infect about 12 to 15 other citizens [12] . Anecdotal evidence indicates that the free drugs for TB patients do not often reach many patients in the northern part of the country due to corruption in the implementation of DOTS. In addition to the above problems, many States in the northern part of the country have peculiar problems. Qualified pharmacists are not directly involved in the distribution of drugs to the patients in some States and the health professionals engaged in the distribution frequently divert the drugs to patent and propriety medicine store license holders for sale.
Despite the various short comings in the implementation of DOTS programme in Nigeria, improvement in treatment success has been recorded in the last couple of years. According to WHO [25] , TB case detection rate has increased from 15.3% in 2001 to 27% in 2005. The treatments success rate for new smear-positive cases treated under DOTS which declined from 65% in 1994 to 32% in 1996 has remained above 72% since 1997 even though the success rate in Nigeria is still lower than those in some African countries including Ethiopia, Kenya, Mozambique, and DR Congo [5] .
One of the major advantages of DOTS programme in Nigeria is that treatment (including the diagnoses and the drugs) is provided free of charge to identified patients. Although Nigeria receives huge support from some donor agencies including WHO and UNDP, there is a wide gap between the resources needed and what is provided. Across the 22 high TB burden countries (Table 2) in 2008, governments was expected to cover 73% of the total costs of TB control while grants will cover 13% (including US$ 200 million from the Global Fund). Reported funding gaps totaling 14% of total costs has been reported across 17 of the countries which include Nigeria but exclude Bangladesh, Ethiopia, India, Indonesia, and South Africa [WHO, 2008] . Proper education of politicians and those in government is needed in the control and allocation of funds. Also, there is the need to mobilize the political class both at the federal, states and local governments to provide the financial and human resources to expand the health care services so that TB patients can be identified and treated. Political commitment will also be required to mobilize the community to educate the people and encourage them. The current DOTS centres in Nigeria need expansion to increase access to care within a limited distance to the affected patients. Although private and public partnership is applied in DOTS programme in Nigeria, there is apparent lack of understanding that over an estimated 70% of the primary health care in the country is mainly controlled by traditional healers, patent and propriety medicine vendors and registered pharmacists. Adequate education of these categories of health care providers, especially in the referral system, is needed to increase the case detection rate and reduce the spread of the disease.
The emphasis on passive case finding in contrast with the identification of cases through screening [27] [28] is a welcome development. This strategy is based on the expectation that passive detection of individuals, who is ill enough to seek medical attention, is far more cost-effective than population-based screening, and that the compliance will be higher in those who have identified themselves as symptomatic [27] . However, the failure of national TB programmes to detect the vast majority of new infectious cases suggests that active screening strategies should be reevaluated in an attempt to improve case detection and, thereby, increase access to TB treatment [29] . Therefore, DOTS expansion will require, at least, screening of close contacts of the treated individuals. Invariably, this will reduce the number of both the latent and the infectious individuals.
Conclusion
Although TB is a worldwide problem, Nigeria is one of the five countries in the world with the highest prevalence rate. The best way to prevent the spread of the disease in any community is to treat the cases immediately to prevent it from infecting other members of the community. If most of those infected are detected early and provided effective treatment, they will go back to the community and society, and be economically productive. Several challenges, including education and funding, are currently facing the DOTS programme in Nigeria. While it is intended that every community within five kilometers in Nigeria has access to a DOTS centre in the country, and the target is that by the year 2010, about 5,000 health facilities will be providing DOTS services, adequate financial support and political will is needed from local, state and federal governments in order for this goal to be achievable because of the reasonable gap between the resources currently accessible and the actual fund needed [5] . With implementation of the Stop TB Strategy, adequate resource mobilization and effective spending are needed to achieve any success.
